These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

475 related items for PubMed ID: 10672239

  • 1. Bioenergetics in Huntington's disease.
    Grünewald T, Beal MF.
    Ann N Y Acad Sci; 1999; 893():203-13. PubMed ID: 10672239
    [Abstract] [Full Text] [Related]

  • 2. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
    Reddy PH, Charles V, Williams M, Miller G, Whetsell WO, Tagle DA.
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun 29; 354(1386):1035-45. PubMed ID: 10434303
    [Abstract] [Full Text] [Related]

  • 3. Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length.
    Becher MW, Kotzuk JA, Sharp AH, Davies SW, Bates GP, Price DL, Ross CA.
    Neurobiol Dis; 1998 Apr 29; 4(6):387-97. PubMed ID: 9666478
    [Abstract] [Full Text] [Related]

  • 4. Huntington's disease: translating a CAG repeat into a pathogenic mechanism.
    MacDonald ME, Gusella JF.
    Curr Opin Neurobiol; 1996 Oct 29; 6(5):638-43. PubMed ID: 8937828
    [Abstract] [Full Text] [Related]

  • 5. HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism.
    Seong IS, Ivanova E, Lee JM, Choo YS, Fossale E, Anderson M, Gusella JF, Laramie JM, Myers RH, Lesort M, MacDonald ME.
    Hum Mol Genet; 2005 Oct 01; 14(19):2871-80. PubMed ID: 16115812
    [Abstract] [Full Text] [Related]

  • 6. Oxidative stress in Huntington's disease.
    Browne SE, Ferrante RJ, Beal MF.
    Brain Pathol; 1999 Jan 01; 9(1):147-63. PubMed ID: 9989457
    [Abstract] [Full Text] [Related]

  • 7. Oxidative damage in Huntington's disease pathogenesis.
    Browne SE, Beal MF.
    Antioxid Redox Signal; 2006 Jan 01; 8(11-12):2061-73. PubMed ID: 17034350
    [Abstract] [Full Text] [Related]

  • 8. Molecular aspects of Huntington's disease.
    Walling HW, Baldassare JJ, Westfall TC.
    J Neurosci Res; 1998 Nov 01; 54(3):301-8. PubMed ID: 9819135
    [Abstract] [Full Text] [Related]

  • 9. Are neuronal intranuclear inclusions the common neuropathology of triplet-repeat disorders with polyglutamine-repeat expansions?
    Davies SW, Beardsall K, Turmaine M, DiFiglia M, Aronin N, Bates GP.
    Lancet; 1998 Jan 10; 351(9096):131-3. PubMed ID: 9439509
    [Abstract] [Full Text] [Related]

  • 10. Mechanisms of neuronal cell death in Huntington's disease.
    Sawa A, Tomoda T, Bae BI.
    Cytogenet Genome Res; 2003 Jan 10; 100(1-4):287-95. PubMed ID: 14526190
    [Abstract] [Full Text] [Related]

  • 11. Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's disease.
    Reddy PH, Shirendeb UP.
    Biochim Biophys Acta; 2012 Feb 10; 1822(2):101-10. PubMed ID: 22080977
    [Abstract] [Full Text] [Related]

  • 12. The early cellular pathology of Huntington's disease.
    Li XJ.
    Mol Neurobiol; 1999 Feb 10; 20(2-3):111-24. PubMed ID: 10966117
    [Abstract] [Full Text] [Related]

  • 13. Aging and neurodegeneration. Molecular mechanisms of neuronal loss in Huntington's disease.
    Lee ST, Kim M.
    Mech Ageing Dev; 2006 May 10; 127(5):432-5. PubMed ID: 16527334
    [Abstract] [Full Text] [Related]

  • 14. How does the Huntington's disease mutation damage cells?
    Rubinsztein DC.
    Sci Aging Knowledge Environ; 2003 Sep 17; 2003(37):PE26. PubMed ID: 13679594
    [Abstract] [Full Text] [Related]

  • 15. [Huntington disease. A review].
    Bonilla E.
    Invest Clin; 2000 Jun 17; 41(2):117-41. PubMed ID: 10961047
    [Abstract] [Full Text] [Related]

  • 16. Neuronal distribution of intranuclear inclusions in Huntington's disease with adult onset.
    Gourfinkel-An I, Cancel G, Duyckaerts C, Faucheux B, Hauw JJ, Trottier Y, Brice A, Agid Y, Hirsch EC.
    Neuroreport; 1998 Jun 01; 9(8):1823-6. PubMed ID: 9665608
    [Abstract] [Full Text] [Related]

  • 17. Dramatic mutation instability in HD mouse striatum: does polyglutamine load contribute to cell-specific vulnerability in Huntington's disease?
    Kennedy L, Shelbourne PF.
    Hum Mol Genet; 2000 Oct 12; 9(17):2539-44. PubMed ID: 11030759
    [Abstract] [Full Text] [Related]

  • 18. Genetics and neuropathology of Huntington's disease.
    Reiner A, Dragatsis I, Dietrich P.
    Int Rev Neurobiol; 2011 Oct 12; 98():325-72. PubMed ID: 21907094
    [Abstract] [Full Text] [Related]

  • 19. Biochemical abnormalities and excitotoxicity in Huntington's disease brain.
    Tabrizi SJ, Cleeter MW, Xuereb J, Taanman JW, Cooper JM, Schapira AH.
    Ann Neurol; 1999 Jan 12; 45(1):25-32. PubMed ID: 9894873
    [Abstract] [Full Text] [Related]

  • 20. Multiple clinical features of Huntington's disease correlate with mutant HTT gene CAG repeat lengths and neurodegeneration.
    Podvin S, Reardon HT, Yin K, Mosier C, Hook V.
    J Neurol; 2019 Mar 12; 266(3):551-564. PubMed ID: 29956026
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.